Scarring data update boosts battered Renovo shares

After seeing its stock price hammered in March on mixed data for the scarring drug Juvista, the UK's Renovo has seen shares bounce back on the news that two more mid-stage studies have produced positive results. And Renovo says it's now poised to begin its first late-stage trial this year. So far, Renovo has mounted 16 early and mid-stage trials of Juvista.

The new results came from a planned 12 month follow-up analysis of two Juvista (human recombinant TGFβ3) Phase II clinical trials: RN1001-0050 and RN1001-0036. Analysis of 12 month data supports a previously stated efficacious dosage window of 50-500ng/100uL/linear cm and researchers concluded that the greatest magnitude of scar improvement effect was seen in 500ng/100uL/linear cm dosed twice, 24 hours apart.

Renovo stock lost half of its value in March, a sign to some analysts of the bipolar mood that influences biotech stock prices.

- see this release
- read the report in Hemscott

Related Articles:
Renovo shares plunge even after 'buy' signals. Stock report
Mixed data for Renovo's scarring therapy. Justiva report
Renovo inks $875M deal for scarring drug. Renovo report
Renovo CEO bullish on partnership prospects. Renovo report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.